A modified grf 1-29 research vial contains a synthesized 29-amino-acid peptide analog of growth hormone-releasing hormone designed specifically for in vitro and preclinical research. Engineered with four strategic amino acid substitutions to resist rapid enzymatic cleavage by dipeptidyl peptidase IV, this GHRH analog provides investigators with a highly stable tool to examine endogenous growth hormone dynamics and downstream IGF-1 signaling cascades.
A modified grf 1-29 research vial contains a synthesized 29-amino-acid peptide analog of growth hormone-releasing hormone designed specifically for in vitro and preclinical research. Engineered with four strategic amino acid substitutions to resist rapid enzymatic cleavage by dipeptidyl peptidase IV, this GHRH analog provides investigators with a highly stable tool to examine endogenous growth hormone dynamics and downstream IGF-1 signaling cascades.
A modified grf 1-29 research vial delivers a high-purity, lyophilized solid containing the tetrasubstituted sequence of human growth hormone-releasing hormone (1-29) amide. Frequently designated as CJC-1295 without DAC (Drug Affinity Complex), Modified GRF 1-29 was developed to overcome the extremely short biological half-life of native GHRH (1-29) and native GHRH (1-44). In standard physiological buffers, native GHRH undergoes rapid N-terminal degradation by the enzyme dipeptidyl peptidase IV (DPP-IV), limiting its utility in physiological assays.
By replacing specific residues—specifically Ala2 with D-Ala, Gln8 with Gln, Asp11 with Ala, and Leu15 with Leu—the structural integrity of the peptide backbone is preserved while retaining high binding affinity for the growth hormone-releasing hormone receptor (GHRH-R). Investigators utilizing a modified grf 1-29 research vial can evaluate acute, pulsatile growth hormone release dynamics without inducing continuous receptor activation or premature receptor down-regulation. All materials supplied by PX1 Research are reserved exclusively for laboratory research use only and are not intended for human or veterinary administration.
The native catalytic core of human GHRH consists of the first 29 amino acids, often termed Sermorelin. While sermorelin retains full biological activity at the GHRH-R, its susceptibility to enzymatic oxidation and cleavage yields a half-life of less than 12 minutes in vitro. Modified GRF 1-29 alters this sequence through target modifications: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2.
The primary modification, the substitution of L-alanine at position 2 with D-alanine, sterically hinders DPP-IV cleavage at the Tyr1-Ala2 peptide bond. Secondary modifications at positions 8, 11, and 15 enhance thermal stability, helical structure retention, and resistance to secondary endopeptidases. As detailed in our comprehensive research hub, these chemical alterations extend the functional half-life of the molecule to approximately 30 minutes in plasma assays while preserving native-like receptor binding affinity.
In preclinical model systems, Modified GRF 1-29 acts as a selective agonist at the GHRH receptor, a G-protein-coupled receptor (GPCR) localized predominantly on anterior pituitary somatotropes. Receptor occupancy activates the Gs alpha subunit, stimulating transmembrane adenylyl cyclase to elevate intracellular cyclic adenosine monophosphate (cAMP) levels. Elevated cAMP subsequently activates protein kinase A (PKA), triggering the influx of extracellular calcium via L-type calcium channels and signaling the exocytosis of stored growth hormone granules.
Because Modified GRF 1-29 lacks the Drug Affinity Complex (DAC) moiety, it does not covalently bind to serum albumin. This fundamental difference allows the compound to clear rapidly following acute receptor binding, permitting normal physiological feedback loops to operate. In vitro assays demonstrate that pulsatile stimulation with Modified GRF 1-29 maintains somatotrope sensitivity, whereas continuous receptor stimulation can lead to GHRH receptor desensitization and internalization. Researchers investigating physiological hormone patterns often reference our broader catalog of growth hormone secretagogues to study synergistic signaling pathways.
In animal studies, the administration of Modified GRF 1-29 has been demonstrated to elevate circulating growth hormone concentrations, driving a corresponding increase in hepatic synthesis of insulin-like growth factor 1 (IGF-1). This somatotropic axis upregulation is central to research evaluating cellular proliferation, myofibrillar protein synthesis, collagen deposition, and lipid oxidation. In murine models of musculoskeletal injury, sustained IGF-1 elevation correlates with accelerated satellite cell activation and extracellular matrix reconstruction.
Furthermore, researchers exploring tissue regeneration often combine GHRH analogs with site-specific repair peptides. Co-incubations or co-administration protocols involving BPC-157 or TB-500 in preclinical models allow investigators to analyze multi-pathway tissue remodeling, contrasting systemic somatotropic elevation with localized angiogenic and cytoskeletal reorganization pathways.
Evaluating secretagogues requires an understanding of structural differences, half-life parameters, and receptor selectivity. While Modified GRF 1-29 provides acute, pulsatile stimulation, CJC-1295 with DAC includes a maleimidoproprionyl derivative that forms a stable covalent bond with circulating albumin, extending its biological half-life to over 6 days in animal models. This long-acting profile produces continuous, non-pulsatile GHRH receptor stimulation, contrasting sharply with the transient kinetic curve of Modified GRF 1-29.
When compared to native-sequence analogs such as Sermorelin, Modified GRF 1-29 exhibits significantly greater resistance to enzymatic cleavage, ensuring higher potency per molar equivalent in cell culture assays. In comparative studies evaluating secretagogue synergies, researchers frequently pair Modified GRF 1-29 with a ghrelin receptor (GHS-R1a) agonist such as Ipamorelin. Dual activation of GHRH-R and GHS-R1a in pituitary culture models yields a synergistic, supra-additive release of growth hormone without inducing significant elevations in serum cortisol or prolactin.
Precision in quantitative bioassays demands rigorous analytical verification of every research peptide lot. PX1 Research adheres to stringent quality control guidelines to ensure that each modified grf 1-29 research vial delivers exact peptide content free from organic impurities, truncated fragments, or heavy metals. All products are manufactured in compliance with cGMP-aligned standards within modern US facilities.
Every production lot undergoes independent analysis at an ISO 17025 accredited analytical laboratory. Quality verification protocol requires dual-spectrum analysis: reverse-phase high-performance liquid chromatography (RP-HPLC) to establish chemical purity at or exceeding 99.0%, and electrospray ionization mass spectrometry (ESI-MS) to confirm exact molecular weight and sequence identity. Additionally, dynamic chromogenic kinetic assays verify that bacterial endotoxin levels remain strictly under <0.01 EU/mg, protecting sensitive cell culture media and animal models from inflammatory interference.
To assist research institutions in selecting the appropriate secretagogue profile for specific experimental protocols, the following criteria table outlines key analytical specifications across common GHRH and GHRP analogs available through our wholesale lab portal:
| Compound | Primary Receptor Target | In Vitro Plasma Half-Life | Secretion Pattern | Endotoxin Limit | Purity Standard | |---|---|---|---|---|---| | Modified GRF 1-29 | GHRH Receptor (GHRH-R) | ~30 Minutes | Acute / Pulsatile | <0.01 EU/mg | ≥99.0% (RP-HPLC) | | CJC-1295 with DAC | GHRH Receptor (GHRH-R) | ~6–8 Days | Continuous / Sustained | <0.01 EU/mg | ≥99.0% (RP-HPLC) | | Sermorelin | GHRH Receptor (GHRH-R) | ~10–12 Minutes | Transient / Pulsatile | <0.01 EU/mg | ≥98.5% (RP-HPLC) | | Ipamorelin | Ghrelin Receptor (GHS-R1a) | ~2 Hours | Selective Pulsatile | <0.01 EU/mg | ≥99.0% (RP-HPLC) |
Lyophilized peptide vials should be stored at -20°C upon receipt to maintain long-term peptide integrity. Before reconstitution, allow the vial to equilibrate to room temperature to prevent atmospheric moisture condensation on the cake. Reconstitution should be performed using sterile Bacteriostatic Water (0.9% benzyl alcohol) or sterile normal saline depending on the experimental requirements. Reconstitution fluid should be directed gently against the glass wall of the vial, followed by gentle swirling; vigorous agitation or vortexing must be avoided to prevent peptide shear stress and denaturation.
Once reconstituted, liquid aliquots of Modified GRF 1-29 should be maintained at 2°C to 8°C and utilized within 30 days. For long-term storage of reconstituted solutions, freeze single-use aliquots at -80°C to avoid repeated freeze-thaw cycles, which degrade peptide sequences over time. For complete laboratory protocol documentation and solubility parameters, consult our centralized research library.
Reliable research outcomes depend on consistent lot-to-lot purity and predictable logistics. PX1 Research processes and ships all orders directly from centralized facilities located in California and Arizona. Orders placed Monday through Friday prior to cutoff cutoffs receive same-day dispatch, minimizing transit delays and ensuring temperature stability during domestic transit.
Principal investigators and laboratory managers requiring high-volume supplies or specialized custom lot reservations can utilize our dedicated wholesale services. Every shipment includes a lot-specific Certificate of Analysis (COA) detailing RP-HPLC chromatograms, mass spectrometry reports, and endotoxin test verification, ensuring complete audit transparency for your research institution.
What is inside a modified grf 1-29 research vial?
A modified grf 1-29 research vial contains 30mg of sterile, lyophilized (freeze-dried) tetrasubstituted human growth hormone-releasing hormone (1-29) amide. It is formulated without fillers or unlisted additives for laboratory research use only.
How does Modified GRF 1-29 differ from CJC-1295 with DAC?
Modified GRF 1-29 lacks the Drug Affinity Complex (DAC) reactive group. Consequently, it does not bind covalently to serum albumin, resulting in a biological half-life of approximately 30 minutes for acute, pulsatile stimulation, whereas CJC-1295 with DAC exhibits a half-life extending several days.
What is the purity level of PX1 Research Modified GRF 1-29?
Every lot of Modified GRF 1-29 undergoes third-party verification via RP-HPLC and mass spectrometry to confirm a chemical purity of at least 99.0%.
What are the endotoxin limits for this compound?
PX1 Research enforces strict quality thresholds, ensuring bacterial endotoxin levels measure under <0.01 EU/mg via chromogenic kinetic testing to prevent inflammatory artifacts in cell or animal models.
How should a modified grf 1-29 research vial be reconstituted in the lab?
Reconstitute by injecting sterile bacteriostatic water or normal saline along the inner glass wall of the vial. Gently swirl until fully dissolved without vortexing or shaking.
What is the recommended storage temperature for lyophilized vials?
Lyophilized vials should be stored at -20°C for long-term stability. Avoid exposure to ambient light and thermal fluctuations.
How long remains reconstituted Modified GRF 1-29 stable?
When reconstituted in bacteriostatic water and stored at 2°C to 8°C, the solution maintains analytical stability for up to 30 days.
Can Modified GRF 1-29 be combined with Ipamorelin in research protocols?
Yes, preclinical studies frequently evaluate the co-administration of Modified GRF 1-29 (a GHRH-R agonist) and Ipamorelin (a GHS-R1a agonist) to examine synergistic growth hormone release kinetics.
Where are PX1 Research compounds manufactured and shipped from?
All PX1 Research compounds are manufactured in US-based GMP-compliant facilities and shipped directly from fulfillment centers in California and Arizona with same-day M-F dispatch.
Can I obtain a lot-specific Certificate of Analysis (COA)?
Yes, every batch is accompanied by a downloadable, lot-specific COA showing exact RP-HPLC purity, ESI-MS mass verification, and endotoxin assay data.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.